Why the study?
Does high-dose chemotherapy followed by non-frozen autologous bone marrow infusion improve remission rates in patients with advanced, relapsed lymphomas?
Does high-dose chemotherapy followed by non-frozen autologous bone marrow infusion improve remission rates in patients with advanced, relapsed lymphomas?
High-dose chemotherapy with non-frozen autologous bone marrow transplantation may be a viable treatment for resistant or relapsed advanced lymphomas.
Answers are grounded in this paper and cite their sources.
May support high-dose chemo with autologous marrow rescue in relapsed lymphomas; hypothesis-generating and requires controlled trials.
Ten patients with advanced, diffuse Hodgkin's and non-Hodgkin's lymphomas responding poorly to the most widely employed primary chemotherapy regimens were treated with a high-dose chemotherapy (HDC) followed by rescue with non-frozen autologous bone marrow infusion (ABMT). Complete remission (CR) was obtained in seven of ten patients (70%) and partial remission in two. Hemopoietic recovery occurred in nine cases. These preliminary results appear to indicate that HDC and non-frozen ABMT may be successfully used in patients with resistant or relapsed lymphomas.
No takes yet. Share an insight, caveat, or question.
Carella et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: